Global Bio-pharma Market review

Bio-pharma Comprehensive Study by Type (Monoclonal Antibodies, Recombinant Proteins, Granulocyte-Colony Stimulating Factor (G-CSF), Interferons, Recombinant Human Insulin, Erythropoietin, Vaccines, Growth Hormones, Purified Proteins, Others), Application (Metabolic Disorders, Oncology, Neurological Disorders, Cardiovascular Diseases, Inflammatory and Infectious Diseases, Others), Sales Channel (Prescriptive, OTC) Players and Region - Global Market Outlook to 2027

Bio-pharma Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 10.1%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Biopharmaceuticals are produced through biotechnology methods involving recombinant DNA techniques, purification processes and hybridoma techniques. Biopharmaceutical production involves the use of biological sources, either live organisms or their active components. A continuous rise in the number of patients suffering from critical diseases, especially in developed countries and developing countries as well, are getting more oriented towards treatments

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Billion)
Key Companies ProfiledPfizer Inc (United States), F. Hoffmann-La Roche AG (Switzerland), Johnson & Johnson Services (United States), Sanofi (France), Amgen (United States), AbbVie (United States), Merck & Co. Inc (United States), Biogen Idec (United States), Bayer AG (Germany), Eli Lilly and Company (United States), Novartis AG (Switzerland) and GlaxoSmithKline Plc (United Kingdom)


According to AMA, the market for Bio-pharma is expected to register a CAGR of 10.1% during the forecast period to 2027. This growth is primarily driven by Increasing Acceptance for Bio-Pharmaceuticals and Significant Market Demand, The Surging Number of Chronic Diseases Patients and Geriatric Population and Rise of Antibiotic-Resistant Bacteria.

Globally, a noticeable market trend is evident Introduction of Innovative BioPharma Worldwide Major Players, such as Pfizer Inc (United States), F. Hoffmann-La Roche AG (Switzerland), Johnson & Johnson Services (United States), Sanofi (France), Amgen (United States), AbbVie (United States), Merck & Co. Inc (United States), Biogen Idec (United States), Bayer AG (Germany), Eli Lilly and Company (United States), Novartis AG (Switzerland) and GlaxoSmithKline Plc (United Kingdom), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Influencing Trend:
Introduction of Innovative BioPharma Worldwide and The Growth of Outsourcing of Bio-Pharmaceutical Labeling and Packaging

Market Growth Drivers:
Increasing Acceptance for Bio-Pharmaceuticals and Significant Market Demand, The Surging Number of Chronic Diseases Patients and Geriatric Population and Rise of Antibiotic-Resistant Bacteria

Challenges:
High Cost, Complexity and Regulatory Scrutiny and Limited R&D Infrastructure in Developing Nations

Restraints:
Need for High-End Manufacturing Requirements and Lack of Proper Supply Chain, and Awareness Among Consumers of New Products

Opportunities:
Increased Demand for Temperature-Sensitive Pharmaceuticals and The Rapid Growth of BioPharm in Asia-Pacific Regions

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Bio-pharma Market
- Analysis about New Entrants in Bio-pharma Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Bio-pharma Study Sheds Light on
— The Bio-pharma Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Bio-pharma industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Bio-pharma industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Monoclonal Antibodies
  • Recombinant Proteins
  • Granulocyte-Colony Stimulating Factor (G-CSF)
  • Interferons
  • Recombinant Human Insulin
  • Erythropoietin
  • Vaccines
  • Growth Hormones
  • Purified Proteins
  • Others
By Application
  • Metabolic Disorders
  • Oncology
  • Neurological Disorders
  • Cardiovascular Diseases
  • Inflammatory and Infectious Diseases
  • Others
By Sales Channel
  • Prescriptive
  • OTC

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Acceptance for Bio-Pharmaceuticals and Significant Market Demand
      • 3.2.2. The Surging Number of Chronic Diseases Patients and Geriatric Population
      • 3.2.3. Rise of Antibiotic-Resistant Bacteria
    • 3.3. Market Challenges
      • 3.3.1. High Cost, Complexity and Regulatory Scrutiny
      • 3.3.2. Limited R&D Infrastructure in Developing Nations
    • 3.4. Market Trends
      • 3.4.1. Introduction of Innovative BioPharma Worldwide
      • 3.4.2. The Growth of Outsourcing of Bio-Pharmaceutical Labeling and Packaging
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Bio-pharma, by Type, Application, Sales Channel and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Bio-pharma (Value)
      • 5.2.1. Global Bio-pharma by: Type (Value)
        • 5.2.1.1. Monoclonal Antibodies
        • 5.2.1.2. Recombinant Proteins
        • 5.2.1.3. Granulocyte-Colony Stimulating Factor (G-CSF)
        • 5.2.1.4. Interferons
        • 5.2.1.5. Recombinant Human Insulin
        • 5.2.1.6. Erythropoietin
        • 5.2.1.7. Vaccines
        • 5.2.1.8. Growth Hormones
        • 5.2.1.9. Purified Proteins
        • 5.2.1.10. Others
      • 5.2.2. Global Bio-pharma by: Application (Value)
        • 5.2.2.1. Metabolic Disorders
        • 5.2.2.2. Oncology
        • 5.2.2.3. Neurological Disorders
        • 5.2.2.4. Cardiovascular Diseases
        • 5.2.2.5. Inflammatory and Infectious Diseases
        • 5.2.2.6. Others
      • 5.2.3. Global Bio-pharma by: Sales Channel (Value)
        • 5.2.3.1. Prescriptive
        • 5.2.3.2. OTC
      • 5.2.4. Global Bio-pharma Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Bio-pharma (Price)
      • 5.3.1. Global Bio-pharma by: Type (Price)
  • 6. Bio-pharma: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer Inc (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Johnson & Johnson Services (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sanofi (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Amgen (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. AbbVie (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Merck & Co. Inc (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Biogen Idec (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bayer AG (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Eli Lilly and Company (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Novartis AG (Switzerland)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. GlaxoSmithKline Plc (United Kingdom)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Bio-pharma Sale, by Type, Application, Sales Channel and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Bio-pharma (Value)
      • 7.2.1. Global Bio-pharma by: Type (Value)
        • 7.2.1.1. Monoclonal Antibodies
        • 7.2.1.2. Recombinant Proteins
        • 7.2.1.3. Granulocyte-Colony Stimulating Factor (G-CSF)
        • 7.2.1.4. Interferons
        • 7.2.1.5. Recombinant Human Insulin
        • 7.2.1.6. Erythropoietin
        • 7.2.1.7. Vaccines
        • 7.2.1.8. Growth Hormones
        • 7.2.1.9. Purified Proteins
        • 7.2.1.10. Others
      • 7.2.2. Global Bio-pharma by: Application (Value)
        • 7.2.2.1. Metabolic Disorders
        • 7.2.2.2. Oncology
        • 7.2.2.3. Neurological Disorders
        • 7.2.2.4. Cardiovascular Diseases
        • 7.2.2.5. Inflammatory and Infectious Diseases
        • 7.2.2.6. Others
      • 7.2.3. Global Bio-pharma by: Sales Channel (Value)
        • 7.2.3.1. Prescriptive
        • 7.2.3.2. OTC
      • 7.2.4. Global Bio-pharma Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Bio-pharma (Price)
      • 7.3.1. Global Bio-pharma by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Bio-pharma: by Type(USD Billion)
  • Table 2. Bio-pharma Monoclonal Antibodies , by Region USD Billion (2016-2021)
  • Table 3. Bio-pharma Recombinant Proteins , by Region USD Billion (2016-2021)
  • Table 4. Bio-pharma Granulocyte-Colony Stimulating Factor (G-CSF) , by Region USD Billion (2016-2021)
  • Table 5. Bio-pharma Interferons , by Region USD Billion (2016-2021)
  • Table 6. Bio-pharma Recombinant Human Insulin , by Region USD Billion (2016-2021)
  • Table 7. Bio-pharma Erythropoietin , by Region USD Billion (2016-2021)
  • Table 8. Bio-pharma Vaccines , by Region USD Billion (2016-2021)
  • Table 9. Bio-pharma Growth Hormones , by Region USD Billion (2016-2021)
  • Table 10. Bio-pharma Purified Proteins , by Region USD Billion (2016-2021)
  • Table 11. Bio-pharma Others , by Region USD Billion (2016-2021)
  • Table 12. Bio-pharma: by Application(USD Billion)
  • Table 13. Bio-pharma Metabolic Disorders , by Region USD Billion (2016-2021)
  • Table 14. Bio-pharma Oncology , by Region USD Billion (2016-2021)
  • Table 15. Bio-pharma Neurological Disorders , by Region USD Billion (2016-2021)
  • Table 16. Bio-pharma Cardiovascular Diseases , by Region USD Billion (2016-2021)
  • Table 17. Bio-pharma Inflammatory and Infectious Diseases , by Region USD Billion (2016-2021)
  • Table 18. Bio-pharma Others , by Region USD Billion (2016-2021)
  • Table 19. Bio-pharma: by Sales Channel(USD Billion)
  • Table 20. Bio-pharma Prescriptive , by Region USD Billion (2016-2021)
  • Table 21. Bio-pharma OTC , by Region USD Billion (2016-2021)
  • Table 22. South America Bio-pharma, by Country USD Billion (2016-2021)
  • Table 23. South America Bio-pharma, by Type USD Billion (2016-2021)
  • Table 24. South America Bio-pharma, by Application USD Billion (2016-2021)
  • Table 25. South America Bio-pharma, by Sales Channel USD Billion (2016-2021)
  • Table 26. Brazil Bio-pharma, by Type USD Billion (2016-2021)
  • Table 27. Brazil Bio-pharma, by Application USD Billion (2016-2021)
  • Table 28. Brazil Bio-pharma, by Sales Channel USD Billion (2016-2021)
  • Table 29. Argentina Bio-pharma, by Type USD Billion (2016-2021)
  • Table 30. Argentina Bio-pharma, by Application USD Billion (2016-2021)
  • Table 31. Argentina Bio-pharma, by Sales Channel USD Billion (2016-2021)
  • Table 32. Rest of South America Bio-pharma, by Type USD Billion (2016-2021)
  • Table 33. Rest of South America Bio-pharma, by Application USD Billion (2016-2021)
  • Table 34. Rest of South America Bio-pharma, by Sales Channel USD Billion (2016-2021)
  • Table 35. Asia Pacific Bio-pharma, by Country USD Billion (2016-2021)
  • Table 36. Asia Pacific Bio-pharma, by Type USD Billion (2016-2021)
  • Table 37. Asia Pacific Bio-pharma, by Application USD Billion (2016-2021)
  • Table 38. Asia Pacific Bio-pharma, by Sales Channel USD Billion (2016-2021)
  • Table 39. China Bio-pharma, by Type USD Billion (2016-2021)
  • Table 40. China Bio-pharma, by Application USD Billion (2016-2021)
  • Table 41. China Bio-pharma, by Sales Channel USD Billion (2016-2021)
  • Table 42. Japan Bio-pharma, by Type USD Billion (2016-2021)
  • Table 43. Japan Bio-pharma, by Application USD Billion (2016-2021)
  • Table 44. Japan Bio-pharma, by Sales Channel USD Billion (2016-2021)
  • Table 45. India Bio-pharma, by Type USD Billion (2016-2021)
  • Table 46. India Bio-pharma, by Application USD Billion (2016-2021)
  • Table 47. India Bio-pharma, by Sales Channel USD Billion (2016-2021)
  • Table 48. South Korea Bio-pharma, by Type USD Billion (2016-2021)
  • Table 49. South Korea Bio-pharma, by Application USD Billion (2016-2021)
  • Table 50. South Korea Bio-pharma, by Sales Channel USD Billion (2016-2021)
  • Table 51. Taiwan Bio-pharma, by Type USD Billion (2016-2021)
  • Table 52. Taiwan Bio-pharma, by Application USD Billion (2016-2021)
  • Table 53. Taiwan Bio-pharma, by Sales Channel USD Billion (2016-2021)
  • Table 54. Australia Bio-pharma, by Type USD Billion (2016-2021)
  • Table 55. Australia Bio-pharma, by Application USD Billion (2016-2021)
  • Table 56. Australia Bio-pharma, by Sales Channel USD Billion (2016-2021)
  • Table 57. Rest of Asia-Pacific Bio-pharma, by Type USD Billion (2016-2021)
  • Table 58. Rest of Asia-Pacific Bio-pharma, by Application USD Billion (2016-2021)
  • Table 59. Rest of Asia-Pacific Bio-pharma, by Sales Channel USD Billion (2016-2021)
  • Table 60. Europe Bio-pharma, by Country USD Billion (2016-2021)
  • Table 61. Europe Bio-pharma, by Type USD Billion (2016-2021)
  • Table 62. Europe Bio-pharma, by Application USD Billion (2016-2021)
  • Table 63. Europe Bio-pharma, by Sales Channel USD Billion (2016-2021)
  • Table 64. Germany Bio-pharma, by Type USD Billion (2016-2021)
  • Table 65. Germany Bio-pharma, by Application USD Billion (2016-2021)
  • Table 66. Germany Bio-pharma, by Sales Channel USD Billion (2016-2021)
  • Table 67. France Bio-pharma, by Type USD Billion (2016-2021)
  • Table 68. France Bio-pharma, by Application USD Billion (2016-2021)
  • Table 69. France Bio-pharma, by Sales Channel USD Billion (2016-2021)
  • Table 70. Italy Bio-pharma, by Type USD Billion (2016-2021)
  • Table 71. Italy Bio-pharma, by Application USD Billion (2016-2021)
  • Table 72. Italy Bio-pharma, by Sales Channel USD Billion (2016-2021)
  • Table 73. United Kingdom Bio-pharma, by Type USD Billion (2016-2021)
  • Table 74. United Kingdom Bio-pharma, by Application USD Billion (2016-2021)
  • Table 75. United Kingdom Bio-pharma, by Sales Channel USD Billion (2016-2021)
  • Table 76. Netherlands Bio-pharma, by Type USD Billion (2016-2021)
  • Table 77. Netherlands Bio-pharma, by Application USD Billion (2016-2021)
  • Table 78. Netherlands Bio-pharma, by Sales Channel USD Billion (2016-2021)
  • Table 79. Rest of Europe Bio-pharma, by Type USD Billion (2016-2021)
  • Table 80. Rest of Europe Bio-pharma, by Application USD Billion (2016-2021)
  • Table 81. Rest of Europe Bio-pharma, by Sales Channel USD Billion (2016-2021)
  • Table 82. MEA Bio-pharma, by Country USD Billion (2016-2021)
  • Table 83. MEA Bio-pharma, by Type USD Billion (2016-2021)
  • Table 84. MEA Bio-pharma, by Application USD Billion (2016-2021)
  • Table 85. MEA Bio-pharma, by Sales Channel USD Billion (2016-2021)
  • Table 86. Middle East Bio-pharma, by Type USD Billion (2016-2021)
  • Table 87. Middle East Bio-pharma, by Application USD Billion (2016-2021)
  • Table 88. Middle East Bio-pharma, by Sales Channel USD Billion (2016-2021)
  • Table 89. Africa Bio-pharma, by Type USD Billion (2016-2021)
  • Table 90. Africa Bio-pharma, by Application USD Billion (2016-2021)
  • Table 91. Africa Bio-pharma, by Sales Channel USD Billion (2016-2021)
  • Table 92. North America Bio-pharma, by Country USD Billion (2016-2021)
  • Table 93. North America Bio-pharma, by Type USD Billion (2016-2021)
  • Table 94. North America Bio-pharma, by Application USD Billion (2016-2021)
  • Table 95. North America Bio-pharma, by Sales Channel USD Billion (2016-2021)
  • Table 96. United States Bio-pharma, by Type USD Billion (2016-2021)
  • Table 97. United States Bio-pharma, by Application USD Billion (2016-2021)
  • Table 98. United States Bio-pharma, by Sales Channel USD Billion (2016-2021)
  • Table 99. Canada Bio-pharma, by Type USD Billion (2016-2021)
  • Table 100. Canada Bio-pharma, by Application USD Billion (2016-2021)
  • Table 101. Canada Bio-pharma, by Sales Channel USD Billion (2016-2021)
  • Table 102. Mexico Bio-pharma, by Type USD Billion (2016-2021)
  • Table 103. Mexico Bio-pharma, by Application USD Billion (2016-2021)
  • Table 104. Mexico Bio-pharma, by Sales Channel USD Billion (2016-2021)
  • Table 105. Bio-pharma: by Type(USD/Units)
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Company Basic Information, Sales Area and Its Competitors
  • Table 115. Company Basic Information, Sales Area and Its Competitors
  • Table 116. Company Basic Information, Sales Area and Its Competitors
  • Table 117. Company Basic Information, Sales Area and Its Competitors
  • Table 118. Bio-pharma: by Type(USD Billion)
  • Table 119. Bio-pharma Monoclonal Antibodies , by Region USD Billion (2022-2027)
  • Table 120. Bio-pharma Recombinant Proteins , by Region USD Billion (2022-2027)
  • Table 121. Bio-pharma Granulocyte-Colony Stimulating Factor (G-CSF) , by Region USD Billion (2022-2027)
  • Table 122. Bio-pharma Interferons , by Region USD Billion (2022-2027)
  • Table 123. Bio-pharma Recombinant Human Insulin , by Region USD Billion (2022-2027)
  • Table 124. Bio-pharma Erythropoietin , by Region USD Billion (2022-2027)
  • Table 125. Bio-pharma Vaccines , by Region USD Billion (2022-2027)
  • Table 126. Bio-pharma Growth Hormones , by Region USD Billion (2022-2027)
  • Table 127. Bio-pharma Purified Proteins , by Region USD Billion (2022-2027)
  • Table 128. Bio-pharma Others , by Region USD Billion (2022-2027)
  • Table 129. Bio-pharma: by Application(USD Billion)
  • Table 130. Bio-pharma Metabolic Disorders , by Region USD Billion (2022-2027)
  • Table 131. Bio-pharma Oncology , by Region USD Billion (2022-2027)
  • Table 132. Bio-pharma Neurological Disorders , by Region USD Billion (2022-2027)
  • Table 133. Bio-pharma Cardiovascular Diseases , by Region USD Billion (2022-2027)
  • Table 134. Bio-pharma Inflammatory and Infectious Diseases , by Region USD Billion (2022-2027)
  • Table 135. Bio-pharma Others , by Region USD Billion (2022-2027)
  • Table 136. Bio-pharma: by Sales Channel(USD Billion)
  • Table 137. Bio-pharma Prescriptive , by Region USD Billion (2022-2027)
  • Table 138. Bio-pharma OTC , by Region USD Billion (2022-2027)
  • Table 139. South America Bio-pharma, by Country USD Billion (2022-2027)
  • Table 140. South America Bio-pharma, by Type USD Billion (2022-2027)
  • Table 141. South America Bio-pharma, by Application USD Billion (2022-2027)
  • Table 142. South America Bio-pharma, by Sales Channel USD Billion (2022-2027)
  • Table 143. Brazil Bio-pharma, by Type USD Billion (2022-2027)
  • Table 144. Brazil Bio-pharma, by Application USD Billion (2022-2027)
  • Table 145. Brazil Bio-pharma, by Sales Channel USD Billion (2022-2027)
  • Table 146. Argentina Bio-pharma, by Type USD Billion (2022-2027)
  • Table 147. Argentina Bio-pharma, by Application USD Billion (2022-2027)
  • Table 148. Argentina Bio-pharma, by Sales Channel USD Billion (2022-2027)
  • Table 149. Rest of South America Bio-pharma, by Type USD Billion (2022-2027)
  • Table 150. Rest of South America Bio-pharma, by Application USD Billion (2022-2027)
  • Table 151. Rest of South America Bio-pharma, by Sales Channel USD Billion (2022-2027)
  • Table 152. Asia Pacific Bio-pharma, by Country USD Billion (2022-2027)
  • Table 153. Asia Pacific Bio-pharma, by Type USD Billion (2022-2027)
  • Table 154. Asia Pacific Bio-pharma, by Application USD Billion (2022-2027)
  • Table 155. Asia Pacific Bio-pharma, by Sales Channel USD Billion (2022-2027)
  • Table 156. China Bio-pharma, by Type USD Billion (2022-2027)
  • Table 157. China Bio-pharma, by Application USD Billion (2022-2027)
  • Table 158. China Bio-pharma, by Sales Channel USD Billion (2022-2027)
  • Table 159. Japan Bio-pharma, by Type USD Billion (2022-2027)
  • Table 160. Japan Bio-pharma, by Application USD Billion (2022-2027)
  • Table 161. Japan Bio-pharma, by Sales Channel USD Billion (2022-2027)
  • Table 162. India Bio-pharma, by Type USD Billion (2022-2027)
  • Table 163. India Bio-pharma, by Application USD Billion (2022-2027)
  • Table 164. India Bio-pharma, by Sales Channel USD Billion (2022-2027)
  • Table 165. South Korea Bio-pharma, by Type USD Billion (2022-2027)
  • Table 166. South Korea Bio-pharma, by Application USD Billion (2022-2027)
  • Table 167. South Korea Bio-pharma, by Sales Channel USD Billion (2022-2027)
  • Table 168. Taiwan Bio-pharma, by Type USD Billion (2022-2027)
  • Table 169. Taiwan Bio-pharma, by Application USD Billion (2022-2027)
  • Table 170. Taiwan Bio-pharma, by Sales Channel USD Billion (2022-2027)
  • Table 171. Australia Bio-pharma, by Type USD Billion (2022-2027)
  • Table 172. Australia Bio-pharma, by Application USD Billion (2022-2027)
  • Table 173. Australia Bio-pharma, by Sales Channel USD Billion (2022-2027)
  • Table 174. Rest of Asia-Pacific Bio-pharma, by Type USD Billion (2022-2027)
  • Table 175. Rest of Asia-Pacific Bio-pharma, by Application USD Billion (2022-2027)
  • Table 176. Rest of Asia-Pacific Bio-pharma, by Sales Channel USD Billion (2022-2027)
  • Table 177. Europe Bio-pharma, by Country USD Billion (2022-2027)
  • Table 178. Europe Bio-pharma, by Type USD Billion (2022-2027)
  • Table 179. Europe Bio-pharma, by Application USD Billion (2022-2027)
  • Table 180. Europe Bio-pharma, by Sales Channel USD Billion (2022-2027)
  • Table 181. Germany Bio-pharma, by Type USD Billion (2022-2027)
  • Table 182. Germany Bio-pharma, by Application USD Billion (2022-2027)
  • Table 183. Germany Bio-pharma, by Sales Channel USD Billion (2022-2027)
  • Table 184. France Bio-pharma, by Type USD Billion (2022-2027)
  • Table 185. France Bio-pharma, by Application USD Billion (2022-2027)
  • Table 186. France Bio-pharma, by Sales Channel USD Billion (2022-2027)
  • Table 187. Italy Bio-pharma, by Type USD Billion (2022-2027)
  • Table 188. Italy Bio-pharma, by Application USD Billion (2022-2027)
  • Table 189. Italy Bio-pharma, by Sales Channel USD Billion (2022-2027)
  • Table 190. United Kingdom Bio-pharma, by Type USD Billion (2022-2027)
  • Table 191. United Kingdom Bio-pharma, by Application USD Billion (2022-2027)
  • Table 192. United Kingdom Bio-pharma, by Sales Channel USD Billion (2022-2027)
  • Table 193. Netherlands Bio-pharma, by Type USD Billion (2022-2027)
  • Table 194. Netherlands Bio-pharma, by Application USD Billion (2022-2027)
  • Table 195. Netherlands Bio-pharma, by Sales Channel USD Billion (2022-2027)
  • Table 196. Rest of Europe Bio-pharma, by Type USD Billion (2022-2027)
  • Table 197. Rest of Europe Bio-pharma, by Application USD Billion (2022-2027)
  • Table 198. Rest of Europe Bio-pharma, by Sales Channel USD Billion (2022-2027)
  • Table 199. MEA Bio-pharma, by Country USD Billion (2022-2027)
  • Table 200. MEA Bio-pharma, by Type USD Billion (2022-2027)
  • Table 201. MEA Bio-pharma, by Application USD Billion (2022-2027)
  • Table 202. MEA Bio-pharma, by Sales Channel USD Billion (2022-2027)
  • Table 203. Middle East Bio-pharma, by Type USD Billion (2022-2027)
  • Table 204. Middle East Bio-pharma, by Application USD Billion (2022-2027)
  • Table 205. Middle East Bio-pharma, by Sales Channel USD Billion (2022-2027)
  • Table 206. Africa Bio-pharma, by Type USD Billion (2022-2027)
  • Table 207. Africa Bio-pharma, by Application USD Billion (2022-2027)
  • Table 208. Africa Bio-pharma, by Sales Channel USD Billion (2022-2027)
  • Table 209. North America Bio-pharma, by Country USD Billion (2022-2027)
  • Table 210. North America Bio-pharma, by Type USD Billion (2022-2027)
  • Table 211. North America Bio-pharma, by Application USD Billion (2022-2027)
  • Table 212. North America Bio-pharma, by Sales Channel USD Billion (2022-2027)
  • Table 213. United States Bio-pharma, by Type USD Billion (2022-2027)
  • Table 214. United States Bio-pharma, by Application USD Billion (2022-2027)
  • Table 215. United States Bio-pharma, by Sales Channel USD Billion (2022-2027)
  • Table 216. Canada Bio-pharma, by Type USD Billion (2022-2027)
  • Table 217. Canada Bio-pharma, by Application USD Billion (2022-2027)
  • Table 218. Canada Bio-pharma, by Sales Channel USD Billion (2022-2027)
  • Table 219. Mexico Bio-pharma, by Type USD Billion (2022-2027)
  • Table 220. Mexico Bio-pharma, by Application USD Billion (2022-2027)
  • Table 221. Mexico Bio-pharma, by Sales Channel USD Billion (2022-2027)
  • Table 222. Bio-pharma: by Type(USD/Units)
  • Table 223. Research Programs/Design for This Report
  • Table 224. Key Data Information from Secondary Sources
  • Table 225. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Bio-pharma: by Type USD Billion (2016-2021)
  • Figure 5. Global Bio-pharma: by Application USD Billion (2016-2021)
  • Figure 6. Global Bio-pharma: by Sales Channel USD Billion (2016-2021)
  • Figure 7. South America Bio-pharma Share (%), by Country
  • Figure 8. Asia Pacific Bio-pharma Share (%), by Country
  • Figure 9. Europe Bio-pharma Share (%), by Country
  • Figure 10. MEA Bio-pharma Share (%), by Country
  • Figure 11. North America Bio-pharma Share (%), by Country
  • Figure 12. Global Bio-pharma: by Type USD/Units (2016-2021)
  • Figure 13. Global Bio-pharma share by Players 2021 (%)
  • Figure 14. Global Bio-pharma share by Players (Top 3) 2021(%)
  • Figure 15. Global Bio-pharma share by Players (Top 5) 2021(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Pfizer Inc (United States) Revenue, Net Income and Gross profit
  • Figure 18. Pfizer Inc (United States) Revenue: by Geography 2021
  • Figure 19. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 20. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2021
  • Figure 21. Johnson & Johnson Services (United States) Revenue, Net Income and Gross profit
  • Figure 22. Johnson & Johnson Services (United States) Revenue: by Geography 2021
  • Figure 23. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 24. Sanofi (France) Revenue: by Geography 2021
  • Figure 25. Amgen (United States) Revenue, Net Income and Gross profit
  • Figure 26. Amgen (United States) Revenue: by Geography 2021
  • Figure 27. AbbVie (United States) Revenue, Net Income and Gross profit
  • Figure 28. AbbVie (United States) Revenue: by Geography 2021
  • Figure 29. Merck & Co. Inc (United States) Revenue, Net Income and Gross profit
  • Figure 30. Merck & Co. Inc (United States) Revenue: by Geography 2021
  • Figure 31. Biogen Idec (United States) Revenue, Net Income and Gross profit
  • Figure 32. Biogen Idec (United States) Revenue: by Geography 2021
  • Figure 33. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 34. Bayer AG (Germany) Revenue: by Geography 2021
  • Figure 35. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 36. Eli Lilly and Company (United States) Revenue: by Geography 2021
  • Figure 37. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 38. Novartis AG (Switzerland) Revenue: by Geography 2021
  • Figure 39. GlaxoSmithKline Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 40. GlaxoSmithKline Plc (United Kingdom) Revenue: by Geography 2021
  • Figure 41. Global Bio-pharma: by Type USD Billion (2022-2027)
  • Figure 42. Global Bio-pharma: by Application USD Billion (2022-2027)
  • Figure 43. Global Bio-pharma: by Sales Channel USD Billion (2022-2027)
  • Figure 44. South America Bio-pharma Share (%), by Country
  • Figure 45. Asia Pacific Bio-pharma Share (%), by Country
  • Figure 46. Europe Bio-pharma Share (%), by Country
  • Figure 47. MEA Bio-pharma Share (%), by Country
  • Figure 48. North America Bio-pharma Share (%), by Country
  • Figure 49. Global Bio-pharma: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Pfizer Inc (United States)
  • F. Hoffmann-La Roche AG (Switzerland)
  • Johnson & Johnson Services (United States)
  • Sanofi (France)
  • Amgen (United States)
  • AbbVie (United States)
  • Merck & Co. Inc (United States)
  • Biogen Idec (United States)
  • Bayer AG (Germany)
  • Eli Lilly and Company (United States)
  • Novartis AG (Switzerland)
  • GlaxoSmithKline Plc (United Kingdom)
Additional players considered in the study are as follows:
Bristol-Myers Squibb Company (United States) , AstraZeneca PLC (United Kingdom) , Abbott Laboratories (United States)
Select User Access Type

Key Highlights of Report


Feb 2024 207 Pages 94 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Bio-pharma Market review Quantitative research analysis
Global Bio-pharma Market review Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Bio-pharma market are Pfizer Inc (United States), F. Hoffmann-La Roche AG (Switzerland), Johnson & Johnson Services (United States), Sanofi (France), Amgen (United States), AbbVie (United States), Merck & Co. Inc (United States), Biogen Idec (United States), Bayer AG (Germany), Eli Lilly and Company (United States), Novartis AG (Switzerland) and GlaxoSmithKline Plc (United Kingdom), to name a few.
is dominating the Bio-pharma Market.
"High Cost, Complexity and Regulatory Scrutiny " is seen as one of the major challenges by many Industry Players of Bio-pharma Market
The Bio-pharma market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Bio-pharma market is expected to see a steady growth rate during projected year 2021 to 2027.

Know More About Global Bio-pharma Market review Report?

Have a Query? Click Here

Other Related Reports

Polio Vaccines Comprehensive Study by Type (IPV (Inactivated Poliovirus Vaccine), OPV (Oral Polio Vaccine)), Application (Hospital, Clinics, Public Services, Others) Players and Region - Global Marke...
$ 3500
Impetigo Drug Comprehensive Study by Type (FMX-102, LTX-109, Mupirocin, Ozenoxacin, Others), Route of Administration (Topical, Oral), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail ...
$ 3500
Clomifene Citrate Comprehensive Study by Application (Hospital, Clinics, Fertility Center), Form (Tablet, Injection), Distribution Channel (Hospital Pharmacies, Medical Stores, Online Pharmacies), En...
$ 3800
Frankincense Oil Comprehensive Study by Type (Natural Frankincense Oil, Synthetic Frankincense Oil), Application (Medicine, Skin care, Oral Care , Others), Distribution Channel (Direct, Indirect (Spe...
$ 3500
Pycnogenol Comprehensive Study by Application (Nutraceutical, Personal and Skin Care Products, Food and Beverages, Health Supplements, Others), Distribution Channel (Direct Sale (Online, Offline), Di...
$ 3450
Protein Kinase Inhibitor Comprehensive Study by Type (Serine/Threonine Protein Kinase Inhibitors, Tyrosine Protein Kinase Inhibitor), Application (Lung Cancer, Breast Cancer, Renal Cell Cancer, Other...
$ 3750